Manufacturer Landscape

“Who makes ibogaine?” does not have one stable answer. The phrase can refer to people selling botanical root bark, processors offering extracts, manufacturers isolating ibogaine as an active pharmaceutical ingredient (API), firms making a finished dosage form, or developers studying related compounds. This page separates those roles because public claims often blur them.

Ibogaine is an indole alkaloid associated with Tabernanthe iboga; the basic botanical context is summarized by Wikipedia’s ibogaine entry. It does not establish the quality, legality, source, identity, or manufacturing standard of any particular item offered for sale.

For a broader orientation to this topic, the site’s starting overview of producers and developers provides the shared vocabulary used across these pages. The aim here is narrower: identify what category a public claim fits, what evidence supports it, and where meaningful gaps remain.

Evidence status is a description of what can be checked in the public record, not an endorsement of a supplier, product, or development program.

“GMP” is frequently used in marketplace copy, but it is not a universal product label. A meaningful claim should identify the manufacturing facility, the applicable jurisdiction, the relevant activity, the product or material covered, the issuing or inspecting authority where applicable, and the date. The U.S. Food and Drug Administration explains its current good manufacturing practice framework in its cGMP regulations resource.

No blanket directory entry should infer regulatory registration, DEA licensing, or GMP status from a company name alone. Where a manufacturer is named in a regulatory filing, peer-reviewed methods paper, official inspection record, or a dated corporate disclosure, that evidence should be recorded exactly and distinguished from a marketing statement. If a claim cannot be connected to a primary record, its status belongs in the unverified category.

• Peer-reviewedSupports a disclosed method, analytical result, or compound discussion; it may not identify a current commercial manufacturer.
• Regulatory filingMay establish that an organization or product was named in a specific filing; verify jurisdiction, date and document scope.
• Company announcementUseful for stated intent or program milestones, but independently confirm manufacturing and certification claims.
• Trade pressCan surface a lead; locate the underlying filing, certificate, company statement or research record before relying on it.
• Unverified reportA name, location, certification, or supply claim circulated without sufficient primary documentation.

Companies working on ibogaine-derived programs, noribogaine, or synthetic analogues can appear in patent filings, scientific literature, investor materials, trial registries and company announcements. Those sources may establish that a program exists, but they do not necessarily establish current drug-product manufacture, a commercial supplier, or an accessible finished product.

Noribogaine is a metabolite of ibogaine and is discussed separately in the scientific and development record; the noribogaine reference overview is a starting point for distinguishing the compound from ibogaine itself. For landscape work, the key question is whether a disclosure names a substance, a development candidate, an investigational product, a manufacturing partner, or only a research direction.

Checkable development status can sometimes be found in the program-status tracker, while a company announcement should retain its own label and date rather than being converted into a regulatory conclusion. Public data may also conflict across later investor updates, archived websites, patents and trial records; the conflict itself should be noted, not silently resolved.

Start by recording the exact organization name, the product description, the claimed country, the public URL, and the date accessed. Then seek a primary record appropriate to the claim: a regulator’s database or filing, a certificate with scope and issuer, a peer-reviewed paper, a corporate release, or an official intellectual-property record. Avoid treating marketplace descriptions, reposted certificates or anonymous directories as final proof.

For U.S.-linked controlled-substance manufacturing claims, distinguish a company’s existence from a specific registration or authorization. The DEA registration information describes the agency’s registration context, but a general page cannot verify a particular supplier. Equivalent checks will depend on the jurisdiction named by the organization.

When information remains incomplete, the responsible conclusion is limited: publicly unverified, unclear scope, outdated record, or conflicting report. The independent ibogaine information resource may provide additional context for readers comparing claims, but no outside page should substitute for source-level verification.

Questions about how this resource distinguishes evidence from assertion are addressed in the organization’s stated approach to clarity and accuracy. This directory is not a recommendation, purchasing guide, clinical service, or legal assessment.